Suppr超能文献

保乳术后放疗对腋窝淋巴结1-3枚阳性的T1-2期乳腺癌患者的影响。

Impact of postmastectomy radiation therapy in T1-2 breast cancer patients with 1-3 positive axillary lymph nodes.

作者信息

Yin Hang, Qu Yuanyuan, Wang Xiaoyuan, Ma Tengchuang, Zhang Haiyang, Zhang Yu, Li Yang, Zhang Siliang, Ma Hongyu, Xing Enkang, Liu Xueying, Xu Qingyong

机构信息

The Department of Breast Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.

The Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.

出版信息

Oncotarget. 2017 Jul 25;8(30):49564-49573. doi: 10.18632/oncotarget.17318.

Abstract

The effect of postmastectomy radiotherapy (PMRT) on T1-2 breast cancer patients with 1-3 positive axillary lymph nodes is controversial up to now. The purpose of this study was to evaluate the impact of postmastectomy radiotherapy for these patients. The prognostic factor effecting locoregional free-survival (LRFS) was also analyzed. In the retrospective clinical data of 1674 eligible patients, survival analysis was performed using the method of Kaplan-Meier and the log-rank test. Cox regression analysis was applied to identify the significant prognostic factors. We found PMRT increased 5-year LRFS (p=0.003), but could not improve 5-year disease-free survival or overall survival statistically. For patients without PMRT, multivariate analysis revealed that age, lymph node ratio and molecule subtype were risk factors effecting LRFS. To further analyze the role of PMRT, we grouped all the patients into low risk group (0 or 1 risk factor) and high risk group (2 or 3 risk factors) depending on these risk factors. We found that in low-risk group, PMRT increased only 5-year LRFS (p=0.012). However, in high-risk group, PMRT increased both 5-year LRFS (p=0.005) and 5-year disease-free survival (p=0.033), but could not improve 5-year overall survival statistically. Thus, these data provide the evidence that PMRT could improve LRFS for T1-2 breast cancer patients with 1-3 positive axillary lymph nodes. Additionally, PMRT could improve LRFS and disease-free survival for high risk patients. Age, lymph node ratio and molecule subtype were high risk factors effecting LRFS in our study.

摘要

目前,乳房切除术后放疗(PMRT)对腋窝淋巴结1 - 3枚阳性的T1-2期乳腺癌患者的影响仍存在争议。本研究旨在评估乳房切除术后放疗对这些患者的影响。同时,还分析了影响局部区域无复发生存期(LRFS)的预后因素。在1674例符合条件患者的回顾性临床数据中,采用Kaplan-Meier法和对数秩检验进行生存分析。应用Cox回归分析确定显著的预后因素。我们发现PMRT可提高5年LRFS(p = 0.003),但在统计学上并不能改善5年无病生存率或总生存率。对于未接受PMRT的患者,多因素分析显示年龄、淋巴结比值和分子亚型是影响LRFS的危险因素。为进一步分析PMRT的作用,我们根据这些危险因素将所有患者分为低风险组(0或1个危险因素)和高风险组(2或3个危险因素)。我们发现,在低风险组中,PMRT仅提高了5年LRFS(p = 0.012)。然而,在高风险组中,PMRT既提高了5年LRFS(p = 0.005),也提高了5年无病生存率(p = 0.033),但在统计学上并不能改善5年总生存率。因此,这些数据表明PMRT可提高腋窝淋巴结1 - 3枚阳性的T1-2期乳腺癌患者的LRFS。此外,PMRT可提高高风险患者的LRFS和无病生存率。在我们的研究中,年龄、淋巴结比值和分子亚型是影响LRFS的高风险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2072/5564788/1394998f7293/oncotarget-08-49564-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验